← Back to Search

Breast Cancer Survivor (BCS) for Breast Cancer (TRAC Trial)

N/A
Recruiting
Led By James Root, PhD
Research Sponsored by Memorial Sloan Kettering Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up within 45 days of participant consent
Awards & highlights

TRAC Trial Summary

The purpose of this study is to look at how differences in cognitive (mental) function develop over time in breast cancer survivors compared to volunteers without a history of cancer (healthy volunteers). Both cancer survivors and healthy volunteers (who are the same age as the cancer survivors) will participate in this study so the researchers can compare the results of neurocognitive testing (which looks at memory, attention, and information processing) on each group of participants.

Eligible Conditions
  • Breast Cancer

TRAC Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~within 45 days of participant consent
This trial's timeline: 3 weeks for screening, Varies for treatment, and within 45 days of participant consent for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
examine cognitive effects
Secondary outcome measures
measure levels of smoking exposure

TRAC Trial Design

2Treatment groups
Experimental Treatment
Group I: Non-cancer Control (NCC)Experimental Treatment2 Interventions
Enrolled participants will be asked to complete a one-time, remote neurocognitive assessment. The neurocognitive assessment will consist of the CogSuite Neurocognitive Battery, an online, remotely deliverable battery of cognitive experimental measures, and a standard battery of remote neuropsychological measures. DNA will be collected via mailed saliva kits to assess Apolipoprotein E (APOE) status.
Group II: Breast Cancer Survivor (BCS)Experimental Treatment3 Interventions
Enrolled participants will be asked to complete a one-time, remote neurocognitive assessment. The neurocognitive assessment will consist of the CogSuite Neurocognitive Battery, an online, remotely deliverable battery of cognitive experimental measures, and a standard battery of remote neuropsychological measures. DNA will be collected via mailed saliva kits to assess Apolipoprotein E (APOE) status.

Find a Location

Who is running the clinical trial?

Memorial Sloan Kettering Cancer CenterLead Sponsor
1,936 Previous Clinical Trials
588,462 Total Patients Enrolled
203 Trials studying Breast Cancer
81,103 Patients Enrolled for Breast Cancer
James Root, PhDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center
3 Previous Clinical Trials
524 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
A Study of Changes in Thinking Related to Aging and Cancer in Breast Cancer Survivors (TRAC)
2024. "A Study of Changes in Thinking Related to Aging and Cancer in Breast Cancer Survivors (TRAC)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06334354.
All > New York City > Philadelphia
~280 spots leftby Mar 2029
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top